{"corpus_id":25487676,"paper_sha":"4783b256c08b14ffdf7cbdbc0af8048b319e4d76","doi":"10.1056/NEJMoa1010971","arxiv_id":null,"pmid":22029979,"pmcid":null,"mag_id":1965416300,"dblp_id":null,"acl_id":null,"title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.","year":2011,"publication_date":"2011-10-26","venue":"New England Journal of Medicine","journal":{"name":"The New England journal of medicine","pages":"\n          1576-85\n        ","volume":"365 17"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, N.I.H., Extramural"],"s2_fields_of_study":["Medicine"],"reference_count":25,"citation_count":959,"influential_citation_count":36,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Anus Diseases","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D001004"},{"d":"Anus Neoplasms","mj":false,"qs":[{"q":"prevention & control","mj":false,"ui":"Q000517"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D001005"},{"d":"Carcinoma in Situ","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"},{"q":"virology","mj":false,"ui":"Q000821"}],"ui":"D002278"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18","mj":false,"ui":"D000068857"},{"d":"Human papillomavirus 11","mj":false,"ui":"D052140"},{"d":"Human papillomavirus 16","mj":false,"ui":"D052162"},{"d":"Human papillomavirus 18","mj":false,"ui":"D052161"},{"d":"Human papillomavirus 6","mj":false,"ui":"D052163"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Papillomavirus Infections","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D030361"},{"d":"Papillomavirus Vaccines","mj":true,"ui":"D053918"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18","ui":"D000068857","reg":"0"},{"n":"Papillomavirus Vaccines","ui":"D053918","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1010971?articleTools=true","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/4783b256c08b14ffdf7cbdbc0af8048b319e4d76","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: The rate of anal cancer is increasing among both women and men, particularly men who have sex with men. Caused by infection with human papillomavirus (HPV), primarily HPV type 16 or 18, anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3). We studied the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 infection in men who have sex with men. METHODS: In a substudy of a larger double-blind study, we randomly assigned 602 healthy men who have sex with men, 16 to 26 years of age, to receive either qHPV or placebo. The primary efficacy objective was prevention of anal intraepithelial neoplasia or anal cancer related to infection with HPV-6, 11, 16, or 18. Efficacy analyses were performed in intention-to-treat and per-protocol efficacy populations. The rates of adverse events were documented. RESULTS: Efficacy of the qHPV vaccine against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 was 50.3% (95% confidence interval [CI], 25.7 to 67.2) in the intention-to-treat population and 77.5% (95% CI, 39.6 to 93.3) in the per-protocol efficacy population; the corresponding efficacies against anal intraepithelial neoplasia associated with HPV of any type were 25.7% (95% CI, -1.1 to 45.6) and 54.9% (95% CI, 8.4 to 79.1), respectively. Rates of anal intraepithelial neoplasia per 100 person-years were 17.5 in the placebo group and 13.0 in the vaccine group in the intention-to-treat population and 8.9 in the placebo group and 4.0 in the vaccine group in the per-protocol efficacy population. The rate of grade 2 or 3 anal intraepithelial neoplasia related to infection with HPV-6, 11, 16, or 18 was reduced by 54.2% (95% CI, 18.0 to 75.3) in the intention-to-treat population and by 74.9% (95% CI, 8.8 to 95.4) in the per-protocol efficacy population. The corresponding risks of persistent anal infection with HPV-6, 11, 16, or 18 were reduced by 59.4% (95% CI, 43.0 to 71.4) and 94.9% (95% CI, 80.4 to 99.4), respectively. No vaccine-related serious adverse events were reported. CONCLUSIONS: Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men. The vaccine had a favorable safety profile and may help to reduce the risk of anal cancer. (Funded by Merck and the National Institutes of Health; ClinicalTrials.gov number, NCT00090285.).","claims":[{"public_id":"cl_5990749891f636075d47f8aea1a9075d","status":"active","text":"Grade 2 or 3 anal intraepithelial neoplasia related to HPV-6, 11, 16, or 18 was reduced by 54.2% in the intention-to-treat population and by 74.9% in the per-protocol efficacy population.","confidence":0.97,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_5990749891f636075d47f8aea1a9075d"},{"public_id":"cl_27b13022840ce1d31c5df1127bba0e2e","status":"active","text":"No vaccine-related serious adverse events were reported in the substudy of men who have sex with men.","confidence":0.96,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_27b13022840ce1d31c5df1127bba0e2e"},{"public_id":"cl_c400ccce62f3607804fe97e57fc733f4","status":"active","text":"Persistent anal infection with HPV-6, 11, 16, or 18 was reduced by 59.4% in the intention-to-treat population and by 94.9% in the per-protocol efficacy population.","confidence":0.97,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_c400ccce62f3607804fe97e57fc733f4"},{"public_id":"cl_03af87913dc5ebb2db93f09cdfe47b9f","status":"active","text":"Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia associated with HPV-6, 11, 16, or 18 was 50.3% in the intention-to-treat population and 77.5% in the per-protocol efficacy population.","confidence":0.98,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_03af87913dc5ebb2db93f09cdfe47b9f"},{"public_id":"cl_5eb307413b9d7f705186d62357383afb","status":"active","text":"Rates of anal intraepithelial neoplasia per 100 person-years were lower in the vaccine group than in the placebo group in both the intention-to-treat population and the per-protocol efficacy population.","confidence":0.97,"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/claims/cl_5eb307413b9d7f705186d62357383afb"}],"concepts":[{"public_id":"co_1da3358632a178a9642b29807cae7136","status":"active","name":"per-protocol efficacy population","description":"An efficacy analysis population used to estimate vaccine effects among participants meeting protocol criteria.","types":["analysis population"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_1da3358632a178a9642b29807cae7136"},{"public_id":"co_2bb9e09bbc2e96d290fb58b01103080b","status":"active","name":"grade 2 or 3 anal intraepithelial neoplasia","description":"High-grade anal intraepithelial neoplasia used as a clinically important disease endpoint.","types":["condition","outcome"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_2bb9e09bbc2e96d290fb58b01103080b"},{"public_id":"co_3189afd2c7fbf1eaa2d7f61abcf77c90","status":"active","name":"vaccine-related serious adverse events","description":"Serious harms attributed to vaccination and monitored as part of the safety evaluation.","types":["safety outcome"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_3189afd2c7fbf1eaa2d7f61abcf77c90"},{"public_id":"co_43f383c3cf1a8a9c3034ddfc53bbf873","status":"active","name":"HPV-6, 11, 16, or 18 infection","description":"Infection with one of the four human papillomavirus types targeted by the quadrivalent vaccine.","types":["infection"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_43f383c3cf1a8a9c3034ddfc53bbf873"},{"public_id":"co_57a5594871bf194ad0c4dce8c4111046","status":"active","name":"placebo group","description":"The comparison group randomly assigned to receive placebo instead of quadrivalent HPV vaccine.","types":["control group"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_57a5594871bf194ad0c4dce8c4111046"},{"public_id":"co_5931d53f704aab38813c9dbe7f2c46a1","status":"active","name":"quadrivalent HPV vaccine","description":"A vaccine targeting human papillomavirus types 6, 11, 16, and 18 in this trial.","types":["intervention"],"aliases":["qHPV"],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_5931d53f704aab38813c9dbe7f2c46a1"},{"public_id":"co_91f53885e4c1ea15d8800cb5d8a64bf4","status":"active","name":"intention-to-treat population","description":"An efficacy analysis population used to estimate vaccine effects among randomized participants.","types":["analysis population"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_91f53885e4c1ea15d8800cb5d8a64bf4"},{"public_id":"co_95ebc8525f454bdddbacd706c2604964","status":"active","name":"anal intraepithelial neoplasia","description":"A precancerous anal epithelial lesion evaluated as an efficacy endpoint in this trial.","types":["condition","outcome"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_95ebc8525f454bdddbacd706c2604964"},{"public_id":"co_965140586f4121154733793e588e84b5","status":"active","name":"men who have sex with men","description":"The population enrolled in the substudy, consisting of healthy male participants aged 16 to 26 years.","types":["population"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_965140586f4121154733793e588e84b5"},{"public_id":"co_c0bb9a09767ea76249dafba0cc17d7b2","status":"active","name":"vaccine group","description":"The trial group randomly assigned to receive quadrivalent HPV vaccine.","types":["intervention group"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_c0bb9a09767ea76249dafba0cc17d7b2"},{"public_id":"co_c1bf81a3ee5c827492fb8e6ac8a663c2","status":"active","name":"persistent anal infection","description":"Ongoing anal infection with HPV types assessed as an infection endpoint in the trial.","types":["infection","outcome"],"aliases":[],"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"url":"https://sah.borca.ai/concepts/co_c1bf81a3ee5c827492fb8e6ac8a663c2"}],"external_ids":{"DOI":"10.1056/NEJMoa1010971","ArXiv":null,"PubMed":22029979,"PubMedCentral":null,"MAG":1965416300,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1010971?articleTools=true","landing_url":"https://www.semanticscholar.org/paper/4783b256c08b14ffdf7cbdbc0af8048b319e4d76","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634198,"paper_uid":"a78cf7b5-442a-40cf-884b-0f8eb9227b54","canonical_identity":{"paper_id":634198,"paper_uid":"a78cf7b5-442a-40cf-884b-0f8eb9227b54","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/25487676"}